Revolution Medicines, Inc. Common Stock (RVMD) Stock Price
RVMDStock
$177.96+258.21%52W
Market Cap$38.14B
P/E—
PEG Ratio—
Div yield—
Beta1.44
RVMD Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)11.15%
Price vs S&P 500 (4W)-6.35%
VGM Score41.16
RVMD Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$2.06 | -$3.06 | -48.77%(-$1.00) | |
| Q1 2026 | -$1.84 | -$2.29 | -24.61%(-$0.45) | |
| Q4 2025 | -$1.56 | -$1.86 | -18.87%(-$0.30) | |
| Q3 2025 | -$1.41 | -$1.61 | -14.34%(-$0.20) | |
| Q2 2025 | -$1.12 | -$1.31 | -16.74%(-$0.19) |
RVMD Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.37
4.31
4.29
4.29
Industry Peers — Biological Products(186)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
RVMDRevolution Medicines, Inc. Common Stock | F | — | B | 3296.2x | — | — | — | $177.96 |
| AMGNAmgen Inc | D | C | A | 6.1x | 9.1% | 74.3% | 2.9% | $432.49 |
| GILDGilead Sciences Inc | C | B | A | 6.4x | 5.5% | 79.6% | 133.6% | $156.19 |
| MRNAModerna, Inc. Common Stock | F | C | A | 39.1x | -27.6% | 36.4% | — | $218.01 |
| ARGXargenx SE American Depositary Shares | D | A | B | 6.6x | 165.2% | 89.8% | — | $819.14 |
| BIIBBiogen Inc. Common Stock | C | D | A | 3.4x | 0.3% | 74.0% | -18.8% | $232.65 |
| BNTXBioNTech SE American Depositary Share | C | C | C | 7.6x | -11.8% | 79.2% | — | $87.71 |
| EXELExelixis Inc | C | B | A | 6.3x | 9.2% | 96.5% | 31.1% | $62.23 |
| HALOHalozyme Therapeutics, Inc. | D | B | A | 8.3x | 41.1% | 82.4% | 22.9% | $121.84 |
| NBIXNeurocrine Biosciences Inc | C | B | B | 4.1x | 34.4% | 98.0% | 2.3% | $135.71 |
| TECHBio-Techne Corp. | D | C | B | 9.4x | -0.4% | 66.2% | 6.0% | $72.57 |
About Revolution Medicines, Inc. Common Stock
Revolution Medicines is a clinical-stage precision oncology company developing targeted therapies for RAS-addicted cancers. The company leverages proprietary structure-based drug discovery capabilities to create small molecules that bind to unconventional RAS variant sites. Its pipeline centers on RAS(ON) Inhibitors designed for use as monotherapy or in combination with other therapeutic agents.